If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Investments Regulatory News (BRH)

  • There is currently no data for BRH

Operational update re certain investments

23 Apr 2020 07:00

RNS Number : 5640K
Braveheart Investment Group plc
23 April 2020
 

23 April 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Operational update on certain strategic investments

Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to provide a further operational update on Kirkstall Limited and Pharm 2 Farm Limited within the context of the COVID-19 pandemic.

Kirkstall Limited ("Kirkstall") (holding 64.67%)

Kirkstall is now collaborating with Animal Free Research UK, the UK's leading non-animal medical research charity, awarding grants to research scientists to implement new and existing techniques to replace the use of animal in trials and research.

During the week commencing 27 April 2020, Animal Free Research UK will launch a call for proposals from UK universities centred around the use of the QuasiVivo technology for research relating to COVID-19. To support this programme, Kirkstall will provide QuasiVivo cell test chambers without charge to research teams selected by Animal Free Research UK, together with technical support to those teams from Kirkstall's founder Dr Malcolm Wilkinson. Dr Williamson has accepted an invitation to sit on the assessment panel to decide which project proposals have most merit.

 

Carla Owen, CEO of both Animal Free Research UK and its Scientific Advisory Panel, will consider research proposals including diagnostic tests, lung disease and associated drug testing, related to COVID-19, from UK universities centred around the use of the QuasiVivo technology. This collaboration will enable research teams to respond quickly and use their skills to help understand how to treat this virus and the QuasiVivo system helps to minimise the need for animal trials.

Pharm 2 Farm Limited ("P2F") (holding 51.72%)

As previously announced, P2F is currently manufacturing medical grade alcohol hand sanitiser gel. In response to demand relating to the COVID-19 pandemic P2F is now planning to increase production to 2000 litres per day by the end of May. In addition to supplying the NHS, P2F are have begun supplying local care homes.

 

The P2F scientific team are also exploring whether further items of PPE can be designed and sourced to meet the requirements of the medical sector, should current conditions persist beyond the Summer.

 

For further information:

 

Braveheart Investment Group plcTrevor Brown, Chief Executive Officer

 

Tel: 01738 587555

 

 

Allenby Capital Limited (Nominated Adviser and Joint Broker) David Worlidge / Nicholas Chambers

 

Tel: 020 3328 5656

 

 

 

Peterhouse Capital Limited (Joint Broker) Heena Karani / Lucy Williams

 

Tel: 020 7469 0936

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUUVNRRAUSUAR
Date   Source Headline
10th Oct 20251:20 pmRNSConfirmation of change of name and website
26th Sep 20257:00 amRNSProposed Change of Name
9th Sep 20257:00 amRNSBlock admission six monthly return
2nd Sep 202511:23 amRNSHolding(s) in Company
1st Aug 20253:04 pmRNSResult of AGM
9th Jul 20252:41 pmRNSFinal Results and Notice of AGM
30th May 20255:00 pmRNSTotal Voting Rights
27th May 20253:15 pmRNSHolding(s) in Company
21st May 20257:00 amRNSResult of Broker Option and Total Voting Rights
16th May 20252:08 pmRNSPlacing to raise £135,000
14th May 202511:55 amRNSHolding(s) in Company
18th Mar 202510:30 amRNSSubscription in IQ-AI Ltd Placing
6th Mar 202510:03 amRNSBlock admission six monthly return
3rd Feb 20257:00 amRNSCancellation of options
20th Jan 20255:32 pmRNSDirector/PDMR Shareholding - acquisition of shares
14th Jan 202511:15 amRNSHolding(s) in Company
8th Jan 20254:54 pmRNSChange of Auditor
10th Dec 20241:28 pmRNSDirector/PDMR Shareholding
9th Dec 202412:16 pmRNSDirector/PDMR Shareholding - acquisition of shares
2nd Dec 20244:22 pmRNSHolding(s) in Company
2nd Dec 20249:05 amRNSDirector/PDMR Shareholding
7th Nov 202411:10 amRNSHolding(s) in Company
7th Nov 202411:06 amRNSDirector/PDMR Shareholding - acquisition of shares
15th Oct 202410:28 amRNSHolding(s) in Company
15th Oct 20247:00 amRNSHalf-year Report
11th Oct 202410:00 amRNSInvestment in IQ-AI Limited and RPT
26th Sep 20249:35 amRNSAppointment of representative to Board of Autins
9th Sep 202410:15 amRNSBlock admission six monthly return
4th Sep 20247:00 amRNSHolding(s) in Company
20th Aug 20245:15 pmRNSHolding(s) in Company
7th Aug 20247:00 amRNSHolding(s) in Company
7th Aug 20247:00 amRNSAcquisition of interest in Image Scan Holdings plc
6th Aug 20245:30 pmRNSHolding(s) in Company
1st Aug 20247:00 amRNSInvestment update – Gyrometric
24th Jul 20247:00 amRNSInvestment update - Kirkstall and Paraytec
24th Jul 20247:00 amRNSHolding(s) in Company
18th Jul 20242:23 pmRNSResult of AGM
15th Jul 20244:27 pmRNSGrant of options
26th Jun 20242:03 pmRNSAcquisition of further interest in Autins Group
21st Jun 20247:00 amRNSFinal Results and Notice of AGM
15th May 202411:22 amRNSRevaluation of portfolio assets
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.